Literature DB >> 29071239

Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question.

Elena Sabini1, Marenza Leo1, Barbara Mazzi1, Roberto Rocchi1, Francesco Latrofa1, Marco Nardi2, Paolo Vitti1, Claudio Marcocci1, Michele Marinò1.   

Abstract

OBJECTIVES: There is a general belief that Graves' orbitopathy (GO) is a "chronic" disease, namely that patients' eyes do not return to how they were before GO appeared. Here, we investigate this issue from both the patient's and the physician's point of view. STUDY
DESIGN: We studied the disappearance of GO, regardless of treatment, in all consecutive patients with a GO history of at least 10 years who came for a follow-up visit over a period of 5 years. Patients underwent an ophthalmological examination and were asked to answer a questionnaire on self-perception related to GO.
RESULTS: We studied 99 consecutive patients with a GO duration ≥10 years. Between the first and the last observation, patients received several types of treatment for their thyroid disease and/or for GO. At the end of follow-up, GO was considered disappeared based on objective criteria in 8 patients (∼8%) and based on subjective criteria in 24 patients (∼24%). When we considered both subjective and objective criteria, only 2 patients (∼2%) had all criteria fulfilled and could be considered as GO-free.
CONCLUSIONS: GO is a chronic disease in the vast majority of patients. Even after a very long time since its onset, complete disappearance is rare, although a minority of patients believe they do not have GO anymore and an even lower proportion do not have relevant GO signs. Our findings have obvious implications in patient management and counseling.

Entities:  

Keywords:  Autoimmunity; Graves' disease; Graves' orbitopathy; Thyroid

Year:  2017        PMID: 29071239      PMCID: PMC5649266          DOI: 10.1159/000477803

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  26 in total

1.  Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves' patients. An exploratory study.

Authors:  M P Mourits; S H C Lombardo; F A van der Sluijs; S Fenton
Journal:  Orbit       Date:  2004-09

2.  Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey.

Authors:  Habib Bilen; Gulay Gullulu; Gungor Akcay
Journal:  Thyroid       Date:  2007-06       Impact factor: 6.568

3.  Normal values of hertel exophthalmometry in children, teenagers, and adults from Tehran, Iran.

Authors:  Mohsen Bahmani Kashkouli; Marzieh Nojomi; Mohammad Mehdi Parvaresh; Mostafa Soltan Sanjari; Mehdi Modarres; Mohammad Mehdi Noorani
Journal:  Optom Vis Sci       Date:  2008-10       Impact factor: 1.973

4.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

Review 5.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

6.  Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.

Authors:  M Leo; L Bartalena; G Rotondo Dottore; E Piantanida; P Premoli; I Ionni; M Di Cera; E Masiello; L Sassi; M L Tanda; F Latrofa; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-10-12       Impact factor: 4.256

7.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

8.  Natural history of thyroid associated ophthalmopathy.

Authors:  P Perros; A L Crombie; P Kendall-Taylor
Journal:  Clin Endocrinol (Oxf)       Date:  1995-01       Impact factor: 3.478

Review 9.  An update on the medical treatment of Graves' hyperthyroidism.

Authors:  Michele Marinò; Francesco Latrofa; Francesca Menconi; Luca Chiovato; Paolo Vitti
Journal:  J Endocrinol Invest       Date:  2014-09-04       Impact factor: 4.256

10.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02
View more
  4 in total

1.  BIOINFORMATIC ANALYSIS IDENTIFIES POTENTIALLY KEY DIFFERENTIALLY EXPRESSED GENES AND PATHWAYS IN ORBITAL ADIPOSE TISSUES OF PATIENTS WITH THYROID EYE DISEASE.

Authors:  F F Zhu; L Z Yang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

2.  Altered Corneal Nerves in Chinese Thyroid-Associated Ophthalmopathy Patients Observed by In Vivo Confocal Microscopy.

Authors:  Lian-Qun Wu; Pei Mou; Zi-Yu Chen; Jin-Wei Cheng; Qi-Hua Le; Ji-Ping Cai; Rui-Li Wei
Journal:  Med Sci Monit       Date:  2019-02-06

3.  In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy.

Authors:  Shengnan Cheng; Yueqi Yu; Jin Chen; Lin Ye; Xinghua Wang; Fagang Jiang
Journal:  BMC Ophthalmol       Date:  2021-06-19       Impact factor: 2.209

4.  Serum Cystatin C Concentrations in Patients with Graves' Ophthalmopathy.

Authors:  Nagehan Can; Ercan Ozsoy; Sabiha Gungor Kobat; Elif Yusufoglu; Nevin Ilhan; Tamer Demir
Journal:  Korean J Ophthalmol       Date:  2020-10-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.